Australia, China, Europe, South Korea and the US have patented the drug which is to be used in the treatment of neuro-degenerative diseases. This drug has been formulated by Suven Life Sciences.
As said by Suven Life Sciences in a BSE filing the patents which they received are valid until 2031, 2030, 2031, 2030 and 2031.
Venkat Jasti, the CEO of Suven Life Sciences said that they are very pleased by the grant of these patents to Suven for their pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.
The company has “secured patents in Australia, China, Europe, South Korea and USA to their new chemical entities for CNS therapy through mechanism of action — H3 Inverse against’’.
With the grant of these new patents, now Suven Life Sciences has a total of 22 granted patents from Australia, 19 from China, 17 from Europe, 17 from South Korea and 23 from the US.
“These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II,” Suven said.
Meanwhile, Suven Life Sciences shares were trading 4.09 per cent up at Rs. 290.30 on the BSE.
View Latest News: